Ryvu Therapeutics SA (RVU) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.553x

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has a cash flow conversion efficiency ratio of -0.553x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-22.84 Million ≈ $-6.29 Million USD) by net assets (zł41.33 Million ≈ $11.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Ryvu Therapeutics SA fund operations to measure how many days the company can operate on defensive assets alone.

Ryvu Therapeutics SA - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ryvu Therapeutics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ryvu Therapeutics SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Semen Baturaja Persero Tbk JK:SMBR	0.008x
Answear.com S.A. WAR:ANR	0.797x
Aris Gold Corporation V:CGC	-1.279x
Evergreen Max Cash Capital Berhad KLSE:0286	-0.151x
Finder Energy Holdings Ltd AU:FDR	-0.630x
q.beyond AG F:QBY	0.035x
Sao Mai Group Corp VN:ASM	-0.024x
Bundamedik Tbk PT JK:BMHS	0.083x

Annual Cash Flow Conversion Efficiency for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Ryvu Therapeutics SA.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł53.83 Million ≈ $14.82 Million	zł-114.10 Million ≈ $-31.40 Million	-2.119x	-135.52%
2024-12-31	zł143.88 Million ≈ $39.60 Million	zł-129.48 Million ≈ $-35.63 Million	-0.900x	-176.29%
2023-12-31	zł259.59 Million ≈ $71.44 Million	zł-84.55 Million ≈ $-23.27 Million	-0.326x	-624.62%
2022-12-31	zł343.39 Million ≈ $94.51 Million	zł21.32 Million ≈ $5.87 Million	0.062x	+118.18%
2021-12-31	zł169.42 Million ≈ $46.63 Million	zł-57.87 Million ≈ $-15.93 Million	-0.342x	-618.46%
2020-12-31	zł223.72 Million ≈ $61.57 Million	zł-10.64 Million ≈ $-2.93 Million	-0.048x	+67.28%
2019-12-31	zł119.76 Million ≈ $32.96 Million	zł-17.40 Million ≈ $-4.79 Million	-0.145x	+22.25%
2018-12-31	zł194.86 Million ≈ $53.63 Million	zł-36.42 Million ≈ $-10.02 Million	-0.187x	-208.91%
2017-12-31	zł64.00 Million ≈ $17.61 Million	zł10.98 Million ≈ $3.02 Million	0.172x	+252.23%
2016-12-31	zł55.71 Million ≈ $15.33 Million	zł-6.28 Million ≈ $-1.73 Million	-0.113x	+67.84%
2015-12-31	zł46.88 Million ≈ $12.90 Million	zł-16.43 Million ≈ $-4.52 Million	-0.350x	+33.84%
2014-12-31	zł9.25 Million ≈ $2.55 Million	zł-4.90 Million ≈ $-1.35 Million	-0.530x	+99.76%
2013-12-31	zł3.13 Million ≈ $861.02K	zł-694.94 Million ≈ $-191.26 Million	-222.129x	-13705.80%
2012-12-31	zł5.53 Million ≈ $1.52 Million	zł-8.90 Million ≈ $-2.45 Million	-1.609x	-208.42%
2011-12-31	zł11.46 Million ≈ $3.15 Million	zł-5.98 Million ≈ $-1.65 Million	-0.522x	+78.85%
2010-12-31	zł1.50 Million ≈ $413.48K	zł-3.71 Million ≈ $-1.02 Million	-2.467x	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$91.37 Million

zł332.01 Million PLN

Market Cap Rank

#19640 Global

#158 in Poland

Share Price

zł14.36

Change (1 day)

-2.58%

52-Week Range

zł14.20 - zł32.40

All Time High

zł75.00